Dupixent Eczema Treatment

dupixent eczema treatment

Dupixent is now available across Canada for adult patients that live with moderate-to-severe atopic dermatitis (AD). Persons living with moderate-to-severe atopic dermatitis can use Dupixent to treat their symptoms. AD is a form of eczema. The condition causes chronic inflammation of the skin, which often appears as a rash. A moderate-to-severe case of AD presents itself with rashes that usually cover much of the body and result in skin dryness, redness, oozing, intense itching, and cracking skin. Itching is the worst symptoms for patients living with atopic dermatitis.

The first biologic therapy drug dupixent targets the primary cause of inflammation rather than just treating the symptoms of the disease. Many of the topical creams treat the symptom of itching and rarely address the underlying cause.

After four months of treatment twice a week, patients in the clinical trial saw an improvement in symptoms after just four months.

Dr. Kim Papp–a dermatologist and trial investigator in Waterloo–said:

“Dupixent is the first and only systemic therapy approved for atopic dermatitis. During the trials, we saw a dramatic improvement in patients with almost a third of patients who received Dupixent reaching a primary outcome of clear or almost clear skin. Availability of new therapies like Dupixent will change the lives of many of our patients.”

Details About Dupixent

Dupixent is a human monoclonal antibody that is designed to inhibit overactive signaling of two specific proteins IL-4 and IL-13. These two proteins are seen as major drivers of the tenacious underlying inflammation. The most common side effects include injection site reactions, cold sores in the mouth, swelling, itching, eye and eyelid inflammation, and redness.

Dupixent is delivered in a pre-filled syringe. This medicine can be self-administered bi-weekly. However, the patient must go to a clinic for their initial loading done in order to proceed with at-home treatment.

Featured Image: DepositPhotos@AndreyPopov

Posted on May 22, 2023